Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44


High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, Carmona SC, Stevens WS.

PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.


Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.


HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.


Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence.

Killick M, Capovilla A, Papathanasopoulos MA.

AIDS Res Hum Retroviruses. 2014 Oct;30(10):1001-5. doi: 10.1089/AID.2014.0042. Epub 2014 Aug 11.


The evaluation of statins as potential inhibitors of the LEDGF/p75-HIV-1 integrase interaction.

Harrison AT, Kriel FH, Papathanasopoulos MA, Mosebi S, Abrahams S, Hewer R.

Chem Biol Drug Des. 2015 Mar;85(3):290-5. doi: 10.1111/cbdd.12384. Epub 2014 Jul 12.


High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.

Steegen K, Levin L, Ketseoglou I, Bronze M, Papathanasopoulos MA, Carmona S, Stevens W.

PLoS One. 2014 May 9;9(5):e97067. doi: 10.1371/journal.pone.0097067. eCollection 2014.


Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.

Cerutti N, Killick M, Jugnarain V, Papathanasopoulos M, Capovilla A.

J Biol Chem. 2014 Apr 11;289(15):10455-65. doi: 10.1074/jbc.M113.539353. Epub 2014 Feb 18.


HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.


Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.


Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa.

Ketseoglou I, Lukhwareni A, Steegen K, Carmona S, Stevens WS, Papathanasopoulos MA.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):289-93. doi: 10.1089/AID.2013.0267. Epub 2013 Dec 13.


Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.


Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.


Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators.

AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5.


Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.


HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

Bronze M, Steegen K, Wallis CL, De Wolf H, Papathanasopoulos MA, Van Houtte M, Stevens WS, de Wit TR, Stuyver LJ; ART-A Consortium.

PLoS One. 2012;7(4):e34708. doi: 10.1371/journal.pone.0034708. Epub 2012 Apr 9.


Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.

AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721.


Modification of HIV-1 reverse transcriptase and integrase activity by gold(III) complexes in direct biochemical assays.

Mphahlele M, Papathanasopoulos M, Cinellu MA, Coyanis M, Mosebi S, Traut T, Modise R, Coates J, Hewer R.

Bioorg Med Chem. 2012 Jan 1;20(1):401-7. doi: 10.1016/j.bmc.2011.10.072. Epub 2011 Nov 3.


Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.

Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J; IAVI Early Infection Cohort Study Group.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):5-12. doi: 10.1089/aid.2010.0030. Epub 2010 Nov 23.


Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient.

Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA.

Virus Genes. 2010 Dec;41(3):358-60. doi: 10.1007/s11262-010-0533-0. No abstract available.


Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infection.

Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos M, Gray G, Sherman G, Coovadia A, Kuhn L.

J Infect Dis. 2010 Nov 1;202(9):1444-53. doi: 10.1086/656535.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk